Belgium· BE-AMP-SAM223562-00
Riamet 20 mg - 120 mg
A artemether and lumefantrine product containing lumefantrine, registered in Belgium by Novartis Pharma. The same ATC class is registered in 7 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Artemether and lumefantrine is registered in 7 of 19 countries.
Countries holding a registration under ATC P01BF01 (artemether and lumefantrine), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 5 of them publish a price we can compare per daily dose
Artemether and lumefantrine · ATC P01BF01
7 / 19 countries
- Belgiumprice
- Finlandprice
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of artemether and lumefantrine costs, country by country.
Normalised to the WHO defined daily dose (0.28 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Artemether and lumefantrine · price per daily dose (0.28 g)
USD · FX 28 Sept 2026
- CH Switzerland$19.10
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Lumefantrine
- Manufacturer
- Novartis Pharma
- Country
- Belgium (BE)
- ATC code
- P01BF01
- ATC class
- Artemether and lumefantrine
- Defined daily dose
- 0.28 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 1
- be_apb1654011
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
1 interaction on record for artemether and lumefantrine.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Artemether and lumefantrine · interactions on record
1 record
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to checkSame class
Other records under P01BF01
Artemether and lumefantrine, as other registers publish it.
- United StatesCOARTEMNovartis Pharmaceuticals Corporation
- FinlandRiametNovartis Finland Oy
- NorwayRiametNovartis (2)
- NetherlandsRiamet 20 mg/120 mg, tablettenNovartis Pharma B.V.
- SwitzerlandRiamet 20 mg/120 mg, TablettenNovartis Pharma Schweiz AG
- SwitzerlandRiamet 20 mg/120 mg, TablettenNovartis Pharma Schweiz AG
- SwitzerlandRiamet 80 mg/480 mg, TablettenNovartis Pharma Schweiz AG
- SwitzerlandRiamet Baby, Tabletten zur Herstellung einer Suspension zum EinnehmenNovartis Pharma Schweiz AG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b94c7c17-5bad-498d-b0b6-ae3bfa5f4cb8 GET /v1/drugs/b94c7c17-5bad-498d-b0b6-ae3bfa5f4cb8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Riamet 20 mg - 120 mg",
"name_fr": "Riamet 20 mg - 120 mg",
"name_nl": "Riamet 20 mg - 120 mg",
"amp_code": "SAM223562-00",
"strengths": [
"120.0000",
"20.0000",
"0.5000"
],
"pack_count": 1,
"substances": [
"Lumefantrine",
"Artemether",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Artemether and Lumefantrine",
"authorisation_numbers": [
"BE223562"
]
}See everything about artemether and lumefantrine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.